Table 1.

Characteristics of the Included Studies

First Author	Trial Name	ClinicalTrials.gov ID Code	Study	Publication	Max Duration	Primary Endpoint	Antagonist	Agonist	Antagonist Sample	Agonist Sample	Metastatic Disease (%)	Baseline CVD (%)	Median Age (y)
Klotz22,23	CS21	NCT00295750	2006-2007	2008	12	Percentage of patients with testosterone level ≤0.5 ng/mL	Degarelix	Leuprolide	409	201	20.0	32.1	73.0
Anderson24	CS28	NCT00831233	2009-2010	2013	3	Change from baseline in IPSS	Degarelix	Goserelin	27	13	35.0	NR	70.0
Mason25	CS30	NCT00833248	2009-2011	2013	3	Change from baseline in prostate size	Degarelix	Goserelin	180	64	Excluded	NR	70.7
Axcrona26	CS31	NCT00884273	2009-2011	2012	3	Change from baseline in prostate size	Degarelix	Goserelin	84	98	29.6	NR	72.0
Shorea	CS35A	NCT01242748	2009-2011	2015	13-36	Percentage of patients with testosterone level ≤0.5 ng/mL	Degarelix	Goserelin	565	282	NR	NR	71.6
Higano27	CS37	NCT00928434	2009-2012	2015	14	Percentage of patients with PSA level ≤4 ng/mL	Degarelix	Leuprolide	225	178	Excluded	NR	72.0
Ozono28	Ozono	NCT01964170	2013-2016	2018	12	Cumulative probability of patients with testosterone level ≤0.5 ng/mL	Degarelix	Goserelin	117	117	18.8	NR	75.7
Saad29	C27002	NCT02083185	2014-2017	2018	12	Percentage of patients with testosterone level ≤0.5 ng/mL	Relugolix	Leuprolide	110	24	NR	NR	70.9
Margel30	Margel	NCT02475057	2015-2019	2019	12	Endothelial function	Degarelix	Any	41	39	26.3	100	71.5
Shore5	HERO	NCT03085095	2017-2020	2020	12	Cumulative probability of testosterone level ≤0.5 ng/mL	Relugolix	Leuprolide	622	308	31.7	13.9	71.0
Lopes9	PRONOUNCE	NCT02663908	2016-2021	2021	12	Time to first occurrence of adjudicated MACE (all-cause death, MI, or stroke)	Degarelix	Leuprolide	275	269	20.4	100	73.0

CVD = cardiovascular disease; HERO = A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer; IPSS = International Prostate Symptom Score; MACE = major adverse cardiovascular event; MI = myocardial infarction; NR = not reported; PRONOUNCE = A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease.

^aData abstracted from www.clinicaltrials.gov.